Date: 31st October, 2026

To,
Corporate Relations Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Company Code: ACCPL

Dear Sir/ Madam,

Subject: Media Release for the half-year ended on 30th September, 2026

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the media release of our Company for the half-year ended on 30th September, 2026, the content of which is self-explanatory.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Pharmaceuticals Limited

ROSHNI DHARMENDRABHAI SHAH
Digitally signed by ROSHNI DHARMENDRABHAI SHAH
Date: 2026.10.31 17:14:03 +05'30'

Roshni Shah
Company Secretary and Compliance Officer

Encl.: as above

Media Release

Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%

Export Contribution Nearly Doubles to 18.15%, Reflecting Growing International Market Presence

Ahmedabad, 31st October, 2026: Accretion Pharmaceuticals Limited (NSE Emerge: ACCPL), an emerging pharmaceutical company engaged in the development, manufacturing and marketing of a diverse range of pharmaceutical formulations, announced its unaudited financial results for the half year ended 30th September 2026.

Key Financial Highlights (Rs. In Crore):

Particulars	H1 FY27	H1 FY26	YoY %	H2 FY26	FY26	FY25	YoY %
Net Revenue	**55.04**	43.74	25.83%	45.89	89.63	57.38	56.20%
EBITDA (including Other Income)	**12.37**	7.18	72.28%	7.96	15.14	11.98	26.38%
EBITDA Margin %	**22.48%**	16.42%	606 bps	17.35%	16.89%	20.87%	(398 bps)
PAT	**8.20**	4.75	72.63%	4.92	9.67	6.79	42.42%
PAT Margin %	**14.90%**	10.87%	403 bps	10.72%	10.79%	11.84%	(105 bps)

Financial Results Highlights for the Half year ended 30th September 2026:

- **Net Revenue in H1 FY27 stood at ₹55.04 crore**, registering a growth of 25.83% YoY, compared to ₹43.74 crore in H1 FY26. The growth was driven by continued business expansion, volume growth, an improved product mix and customer additions. The Company further strengthened its international presence, with export contribution increasing to 18.15% of total revenue from 9.16% in H1 FY26, reflecting progress in its efforts to expand its global market reach.

- **EBITDA (including Other Income) increased 72.28% YoY to ₹12.37 crore, compared to ₹7.18 crore in H1 FY26.** EBITDA margin improved significantly to 22.48% from 16.42%, representing an expansion of 606 basis points. The improvement reflects better operating performance, enhanced profitability and a favourable business mix, supported by the Company's continued focus on operational efficiencies and cost management.

- **Profit After Tax (PAT) rose 72.63% YoY to ₹8.20 crore in H1 FY27, compared to ₹4.75 crore in H1 FY26,** with PAT margin improving to 14.90% from 10.87%, reflecting an expansion of 403 basis points. The growth in profitability was driven by improved operating performance and stronger earnings during the period.

- Basic EPS for H1 FY27 stood at ₹7.38, compared to ₹4.61 in H1 FY26, reflecting strong growth in earnings and improved profitability.

Management Comment:

Commenting on the Company's performance, **Mr. Vivek Ashok Kumar Patel, Promoter, Managing Director, Accretion Pharmaceuticals Limited said:**

"H1 FY27 has been a strong period for Accretion Pharmaceuticals Limited, with healthy revenue growth and significant improvement in profitability. We achieved revenue of ₹55.04 crore, registering 25.83% YoY growth, while EBITDA (including Other Income) increased by 72.28% to ₹12.37 crore and PAT grew by 72.63% to ₹8.20 crore. The improvement in margins reflects our continued focus on operational efficiency, cost management and business growth. We are particularly encouraged by the strong growth in our export business. Export contribution to total revenue increased significantly to 18.15% in H1 FY27 from 9.16% in H1 FY26, reflecting our growing international presence and efforts to expand into new markets.

Going forward, we remain focused on strengthening our manufacturing capabilities, expanding our product portfolio, growing our own-brand exports and exploring new licensing and product development opportunities.

*Aligned with India's ambition to become the **'Pharmacy of the World**,' we aim to strengthen our presence in both domestic and international markets through the manufacturing and supply of quality pharmaceutical products. We remain committed to sustainable growth, building trusted partnerships and creating long-term value for our stakeholders. **Together, we grow with purpose, lead with quality and care for a healthier world.***

Thank you for your ongoing support and trust in Accretion Pharmaceuticals Limited."

Company Overview

Established in 2012 and headquartered in Ahmedabad, Gujarat, Accretion Pharmaceuticals Limited is a growing pharmaceutical company listed on the NSE Emerge platform on 21st May, 2025. The Company is engaged in the development, manufacturing and marketing of high-quality generic and branded pharmaceutical formulations. Its product portfolio includes tablets, capsules, oral liquids, oral powders and external preparations. Operating from its state-of-the-art manufacturing facility in Ahmedabad, the Company offers a range of business solutions, including CDMO services, own-brand exports, and licensing and product development, catering to the requirements of domestic marketers, merchant exporters and international clients.

Accretion has established its presence in more than 30+ countries, particularly across Africa, Southeast Asia and Latin America. The Company holds several quality certifications and regulatory approvals, including WHO-cGMP, GLP, GMP approvals from Cambodia, Rwanda, Nigeria, Malawi, Cameroon and Congo (DR), along with ISO 9001:2015, ISO 14001:2015 and ISO 22000:2018 certifications.

With an experienced Board of Directors and professional management team, the Company continues to focus on quality manufacturing, product portfolio expansion and strengthening its presence in domestic and international markets.

For more details please visit: www.accretionpharma.com

For further information please contact:
Roshni Shah
Company Secretary & Compliance Officer
Accretion Pharmaceuticals Limited
E-mail: compliance@accretionpharma.com

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*